Ipilimumab and Nivolumab in Renal Cell Carcinoma: Real-World Experience in Rare Variant Renal Cell Carcinoma, Brain Metastases and Impact of Immune-Related Adverse Events and Steroid Use
Clinical Genitourinary Cancer · 2026-02 · 24 (1) · 102470
DOI: 10.1016/j.clgc.2025.102470 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genitourinary Cancer, 2026-02. Verfasst von Tobias Peres und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom. Electronic address: tobias.peres@rmh.nhs.uk. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Nivolumab, Ipilimumab, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Stiftung Krebsforschung Schweiz.
Themen: Patientensicherheit
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: To evaluate the efficacy and toxicity of ipilimumab and nivolumab in advanced clear cell renal cell carcinoma (ccRCC) and rare variant RCC, and assess the impact of immune-related adverse events (irAEs) and steroid use on survival. METHODS: This retrospective study included patients with advanced ccRCC and rare variant RCC treated with first-line ipilimumab and nivolumab at the Royal Marsden Hospital between 2016 and 2025. Survival, toxicity, and the impact of irAEs and steroid use were analyzed using landmark and time-dependent methods. KEY FINDINGS AND LIMITATIONS: Among 154 patients, 35 had rare variant RCC and 18 had brain metastases (BM). Median follow-up was 20.3 months (ccRCC) and 24.2 months (rare variants). Median overall survival (OS) was 31.9 months (95% CI, 23.5-59.1) for ccRCC and 25.9 months (95% CI, 21.9-not estimable (NE)) for rare variants. Median progression-free survival (PFS) was 9.0 months (95% CI, 7.1-12.8) and 7.2 months (95% CI, 4.6-NE), respectively. Objective response rates (ORR) were 41.0% (ccRCC) and 38.2% (rare variants). In BM patients, median OS was 14.5 months (95% CI, 8.3-NE), PFS 6.2 months (95% CI, 3.3-NE), and ORR 27.8%. Grade 3-4 irAEs occurred in 28.4% and were associated with longer OS at 6-week landmark (NR vs. 23.1 months, P = .033). Prednisone ≥ 40 mg was associated with improved OS (61.2 vs. 22.3 months, P = .021), confirmed on multivariable analysis. Limitations include small sample size and retrospective design. CONCLUSIONS AND CLINICAL IMPLICATIONS: Ipilimumab and nivolumab demonstrated real-world efficacy in both ccRCC and rare variant RCC. Grade 3-4 irAEs and the use of high-dose steroids for their management were associated with improved OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom. Electronic address: tobias.peres@rmh.nhs.uk.
- Division of Medical Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.
Förderung
- Stiftung Krebsforschung Schweiz
Zitieren
APA
Peres, T., & Larkin, J. (2026). Ipilimumab and Nivolumab in Renal Cell Carcinoma: Real-World Experience in Rare Variant Renal Cell Carcinoma, Brain Metastases and Impact of Immune-Related Adverse Events and Steroid Use. Clinical Genitourinary Cancer, 24(1), 102470. https://doi.org/10.1016/j.clgc.2025.102470
Vancouver
Peres T, Larkin J. Ipilimumab and Nivolumab in Renal Cell Carcinoma: Real-World Experience in Rare Variant Renal Cell Carcinoma, Brain Metastases and Impact of Immune-Related Adverse Events and Steroid Use. Clinical Genitourinary Cancer. 2026;24(1):102470. doi:10.1016/j.clgc.2025.102470
BibTeX
@article{Peres2026,
author = {Peres, Tobias and Larkin, James},
title = {Ipilimumab and Nivolumab in Renal Cell Carcinoma: Real-World Experience in Rare Variant Renal Cell Carcinoma, Brain Metastases and Impact of Immune-Related Adverse Events and Steroid Use},
journal = {Clinical Genitourinary Cancer},
year = {2026},
volume = {24},
number = {1},
pages = {102470},
doi = {10.1016/j.clgc.2025.102470}
}
EUVIMED